Safety and efficacy of BAY 81‐8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme

BAY 81‐8973 is a recombinant factor VIII (rFVIII) with the same amino acid sequence as Bayer's sucrose‐formulated rFVIII (rFVIII‐FS) but manufactured with certain more advanced technologies.

[1]  J. Oldenburg,et al.  Efficacy and safety of BAY 81‐8973, a full‐length recombinant factor VIII: results from the LEOPOLD I trial , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[2]  R. Ljung,et al.  BAY 81‐8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[3]  S. Garger,et al.  Pharmacokinetic properties of BAY 81‐8973, a full‐length recombinant factor VIII , 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

[4]  J. Mahlangu,et al.  Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II) , 2015, Journal of thrombosis and haemostasis : JTH.

[5]  A. Savic,et al.  Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian™ clinical trials , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

[6]  J. Mahlangu,et al.  Guidelines for the management of hemophilia , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[7]  J. Jordan,et al.  Viral pathogens , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

[8]  C. Négrier,et al.  Surgical evaluation of a recombinant factor VIII prepared using a plasma/albumin-free method: Efficacy and safety of Advate in previously treated patients , 2008, Thrombosis and Haemostasis.

[9]  L. Havekes,et al.  The B domain of coagulation factor VIII interacts with the asialoglycoprotein receptor , 2005, Journal of thrombosis and haemostasis : JTH.

[10]  E. Merchan.  The haemophilic pseudotumour , 2004, International Orthopaedics.

[11]  E. Rodríguez‐Merchán.  The haemophilic pseudotumour , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

[12]  M. Ragni,et al.  Efficacy of a sucrose‐formulated recombinant factor VIII used for 22 surgical procedures in patients with severe haemophilia A , 2000, Haemophilia : the official journal of the World Federation of Hemophilia.

[13]  A. Batorova,et al.  Intermittent injections vs. continuous infusion of Factor VIII in haemophilia patients undergoing major surgery , 2000, British journal of haematology.